A study of NBI-74788 for the treatment of classic, 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH)
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2018
At a glance
- Drugs NBI 74788 (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 05 Nov 2018 According to a Neurocrine Biosciences media release, data are expected during the first quarter of 2019.
- 31 Jul 2018 According to a Neurocrine Biosciences media release, the company expects to to be available later in 2018.
- 13 Feb 2018 Status changed from planning to recruiting, according to a Neurocrine Biosciences media release.